Ligand Pharmaceuticals Incorporated (LGNDZ)
OTCMKTS · Delayed Price · Currency is USD
0.0020
0.00 (0.00%)
At close: Mar 5, 2026

Ligand Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
268.09167.13131.31196.25241.54
Revenue Growth (YoY)
60.40%27.28%-33.09%-18.75%47.68%
Cost of Revenue
14.5511.0710.5152.8362.18
Gross Profit
253.54156.06120.8143.42179.37
Selling, General & Admin
92.4578.6552.7970.0646.79
Depreciation & Amortization Expenses
32.7132.9633.6534.2434.22
Research & Development
81.1821.4324.5436.0832.11
Other Operating Expenses
6.245.63---37.6
Operating Income
41-22.619.823.04103.85
Interest Income
13.668.067.712.050.89
Interest Expense
-4.72-3.04-0.66-1.8-19.62
Other Non-Operating Income (Expense)
117.9625.1251.7232.97-31.65
Total Non-Operating Income (Expense)
126.930.1458.7733.22-50.38
Pretax Income
167.97.5468.5936.2653.47
Provision for Income Taxes
-34.51-6.55-9.84-41.234.15
Net Income
124.45-4.0352.15-33.3657.14
Earnings From Discontinued Operations
---1.67-28.14-19.22
Net Income to Common
124.45-4.0352.15-33.3657.14
Shares Outstanding (Basic)
1918171717
Shares Outstanding (Diluted)
2018181717
Shares Change (YoY)
10.96%3.00%5.27%-2.19%2.50%
EPS (Basic)
6.44-0.223.02-0.313.44
EPS (Diluted)
6.13-0.222.94-0.313.31
EPS Growth
----748.72%
Free Cash Flow
48.9195.2346.06119.9370.04
Free Cash Flow Growth
-48.64%106.76%-61.60%71.23%39.72%
Free Cash Flow Per Share
2.415.212.597.114.06
Gross Margin
94.57%93.37%91.99%73.08%74.26%
Operating Margin
15.29%-13.53%7.48%1.55%42.99%
Profit Margin
46.42%-2.41%40.98%-2.66%31.61%
FCF Margin
18.24%56.98%35.07%61.11%29.00%
EBITDA
74.7812.6346.3454.57154.92
EBITDA Margin
27.89%7.56%35.29%27.81%64.14%
EBIT
41-22.619.823.04103.85
EBIT Margin
15.29%-13.53%7.48%1.55%42.99%
Effective Tax Rate
-20.55%-86.92%-14.35%-113.71%7.76%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.